Keyword: Auvi-Q

Novartis' Sandoz is stirring things up in the epinephrine market—and it's about to stir things up in the pediatric epinephrine market, too.

At least three new emergency epinephrine marketers are challenging longtime market leader Mylan and its EpiPen.

Mylan's EpiPen supply issues have been well documented, and now a competitor is seeking to steal market share through a deal with Walgreens.

Privately held Kaléo has a supply of epinephrine auto injectors and is making sure the public knows its version is available.

Novartis has decided to jump onto EpiPen’s playing field with a deal for U.S. rights to Symjepi, the Adamis epinephrine product approved last June.

Kaléo, maker of EpiPen rival Auvi-Q, returns to the wide world of sports to highlight severe allergies, this time with racecar driver Elliott Sadler.

Not every baseball fan wants peanuts and Cracker Jack—especially fans with severe allergies. But Kaléo has a solution.

Several exclusions in Express Scripts' new formulary, or a lack thereof in some fields, highlight trends in the drug business.

Express Scripts is suing Kaléo Pharma for $14.5 million in unpaid rebates triggered by controversial Evzio price hikes.

Mylan agreed to pay $465M to settle a federal probe into underpaid Medicaid rebates, but that's less than half the cost to taxpayers, HHS says.